REUTERS\/Nir Elias<\/span><\/p>\n Aurora Cannabis<\/a>, the Canadian cannabis producer that was reportedly in talks with Coca-Cola<\/a> to make a drink infused with CBD,\u00a0one of the nonpsychoactive compounds found in cannabis, \u2014 that didn’t lead to a deal \u2014 is targeting a US stock-market debut in October, a report says.\u00a0<\/p>\n “We’re targeting the month of October to establish a US listing,” Cam Battley, Aurora’s\u00a0<\/span>chief corporate officer, told the Financial Post<\/a> on Tuesday.\u00a0<\/span><\/p>\n An initial public offering on US markets has become more attractive in recent weeks as cannabis stocks have seen mouthwatering gains. It all started when Canopy Growth received a $4 billion investment from Constellation Brands<\/a>, the beverage maker behind Corona beer and Svedka vodka, sending its stock up more than 22% in a single day. <\/span><\/p>\n And rival Tilray<\/a> has seen its stock surge more than 900% following its July IPO. It was recently boosted by word the company had received clearance\u00a0to export medical marijuana to the United States<\/a>\u00a0for a clinical drug trial.\u00a0<\/span><\/p>\n But a listing won’t come without some risk. A Politico report published last week said that workers of Canadian cannabis companies could face a lifetime travel ban to the US<\/a>.\u00a0<\/span><\/p>\n “If you work for the industry, that is grounds for inadmissibility,” Todd Owen, the executive assistant commissioner for the US Customs and Border Protection’s Office of Field Operations, told Politico.<\/span><\/p>\n\n